USSTOCK.TODAY
Market Closed
Log in Sign up

Hemab Therapeutics Holdings to Initiate Phase 3 Clinical Trial for Glanzmann Thrombasthenia

The Motley Fool +1 · ·by G4L

COAG
COAG Hemab Therapeutics Holdings Inc
$38.77 -9.44%
View chart & analysis →
  1. 1Hemab Therapeutics Holdings announced yesterday that it has initiated SOLARA, a pivotal Phase 3 clinical trial of sutasymic for Glanzmann thrombasthenia.
  2. 2Last week, Hemab Therapeutics Holdings released initial Phase 2b clinical data for sutasymic regarding Factor VII deficiency.
  3. 3As of September 30, Hemab's cash, cash equivalents, and securities totaled $430.2 million.

So what's the key point?

Hemab Therapeutics Holdings has started a Phase 3 clinical trial for a treatment for platelet dysfunction. The company holds $430.2 million in cash.

Source The Motley Fool +1 · View original ↗

Related 3-line summaries

D-Wave Quantum Inc. Q3 Revenue Up 21% and Bookings Surge 611% The Motley Fool +1 · 29m agoS&P 500 Plunge and Diversification for Portfolio Protection The Motley Fool +1 · 24m agoTSMC October revenue up approximately 60% year-on-year; imports of Taiwanese products surpass Chinese products The Motley Fool +1 · 24m ago
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news